BR112014027019A2 - processo para purificar proteína circunsporozoíta p. falciparum recombinante; formulação líquida estável de proteína circunsporozoíta p. falciparum recombinante; e processo para manter de forma estável rcsp em uma formulação líquida estável - Google Patents

processo para purificar proteína circunsporozoíta p. falciparum recombinante; formulação líquida estável de proteína circunsporozoíta p. falciparum recombinante; e processo para manter de forma estável rcsp em uma formulação líquida estável

Info

Publication number
BR112014027019A2
BR112014027019A2 BR112014027019A BR112014027019A BR112014027019A2 BR 112014027019 A2 BR112014027019 A2 BR 112014027019A2 BR 112014027019 A BR112014027019 A BR 112014027019A BR 112014027019 A BR112014027019 A BR 112014027019A BR 112014027019 A2 BR112014027019 A2 BR 112014027019A2
Authority
BR
Brazil
Prior art keywords
falciparum
stable liquid
recombinant
liquid formulation
circumsporozoite protein
Prior art date
Application number
BR112014027019A
Other languages
English (en)
Other versions
BR112014027019B1 (pt
Inventor
Cantin Greg
Allen Jeffrey
Haverstock Ryan
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of BR112014027019A2 publication Critical patent/BR112014027019A2/pt
Publication of BR112014027019B1 publication Critical patent/BR112014027019B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “processo para purificar proteína circunsporozoíta p. falciparum recombinante; formulação líquida estável de proteína circunsporozoíta p. falciparum recombinante; e processo para manter de forma estável rcsp em uma formulação líquida estável” trata-se de processos para purificar proteína circunsporozoíta plasmodium falciparum recombinante de alta qualidade em alto rendimento. esse processo fornece rcsp em alto rendimento sem a necessidade de desnaturar e redobrar a proteína. a presente invenção supera obstáculos previamente encontrados no campo, incluindo dimerização agregação e degradação de terminal n de rcsp. o processo fornecido pela invenção é escalável e pode ser aplicado a grandes lotes de fermentação. a invenção também refere-se a formulações líquidas estáveis de proteína circunporozoita p. falciparum recombinante, e processos para manter de modo estável rcsp em uma formulação líquida estável.
BR112014027019-8A 2012-05-01 2013-04-22 Processo para purificar proteína circunsporozoíta p. falciparum recombinante; formulação líquida estável de proteína circunsporozoíta p. falciparum recombinante; e processo para manter de forma estável rcsp em uma formulação líquida estável BR112014027019B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261641105P 2012-05-01 2012-05-01
US61/641,105 2012-05-01
US13/844,261 US9169304B2 (en) 2012-05-01 2013-03-15 Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US13/844,261 2013-03-15
PCT/US2013/037656 WO2013165732A1 (en) 2012-05-01 2013-04-22 Process for purifying recombinant plasmodium falciparum circumsporozoite protein

Publications (2)

Publication Number Publication Date
BR112014027019A2 true BR112014027019A2 (pt) 2017-07-11
BR112014027019B1 BR112014027019B1 (pt) 2022-09-06

Family

ID=49514758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027019-8A BR112014027019B1 (pt) 2012-05-01 2013-04-22 Processo para purificar proteína circunsporozoíta p. falciparum recombinante; formulação líquida estável de proteína circunsporozoíta p. falciparum recombinante; e processo para manter de forma estável rcsp em uma formulação líquida estável

Country Status (16)

Country Link
US (2) US9169304B2 (pt)
EP (1) EP2844666B1 (pt)
JP (1) JP6238967B2 (pt)
KR (1) KR102087461B1 (pt)
CN (1) CN104379596B (pt)
AR (1) AR090900A1 (pt)
AU (1) AU2013256757B2 (pt)
BR (1) BR112014027019B1 (pt)
CA (1) CA2870198C (pt)
MX (1) MX352093B (pt)
MY (1) MY166380A (pt)
NZ (1) NZ630121A (pt)
SG (1) SG11201407108TA (pt)
TW (1) TWI630213B (pt)
WO (1) WO2013165732A1 (pt)
ZA (1) ZA201407420B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
EP3092002B1 (en) 2014-01-09 2019-09-25 Kentucky Bioprocessing, Inc. Method of purifying monoclonal antibodies
CN106459876A (zh) * 2014-03-28 2017-02-22 促接合因子股份有限公司 治疗性细菌的小菌落变异株的制备
WO2016089782A1 (en) 2014-12-01 2016-06-09 Pfenex Inc. Fusion partners for peptide production
CN109966319B (zh) * 2017-12-22 2022-11-22 四川好医生攀西药业有限责任公司 一种康复新液的原料及其制备方法和应用
CN108559721A (zh) * 2018-05-15 2018-09-21 北京师范大学 一种净化空气的复合微生物菌剂及其应用
US20230241194A1 (en) * 2020-06-29 2023-08-03 Michael Theisen Pre-erythrocytic malaria vaccines

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
ZA855232B (en) 1984-07-23 1986-02-26 Univ New York Protective peptide antigen corresponding to plasmodium falciparum circumsporozoite protein
US5178861A (en) 1984-09-12 1993-01-12 New York University Cross-reactive and protective epitopes of circumsporozoite proteins
NZ213303A (en) 1984-09-12 1988-09-29 Univ New York Plasmodium protein, dna sequence and vaccine
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
ATE118784T1 (de) 1985-07-12 1995-03-15 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
CA1340373C (en) 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0252588A3 (en) 1986-05-12 1989-07-12 Smithkline Beecham Corporation Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
WO1988005817A1 (en) 1987-01-30 1988-08-11 Smith Kline - Rit S.A. Expression of the p. falciparum circumsporozoite protein by yeast
JP2918895B2 (ja) 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
AU625713B2 (en) 1988-02-19 1992-07-16 Microgenesys, Inc. Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5028425A (en) 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria
EP0768377A1 (en) * 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
JPH03504082A (ja) 1988-12-21 1991-09-12 スミスクライン・バイオロジカルズ 昆虫細胞によるプラスモディウム属サーカムスポロゾイト蛋白の発現
WO1990009444A1 (en) 1989-02-10 1990-08-23 Genesit Oy A method for producing pertussis toxin subunits
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
NZ233255A (en) 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
DK0396964T3 (da) 1989-04-28 1995-10-30 Sclavo Spa Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
ES2058821T3 (es) 1989-11-28 1994-11-01 Wellcome Found Vacunas.
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
WO1992017204A1 (en) 1991-04-01 1992-10-15 The United States Of America, Represented By The Secretary, United States Department Of Commerce Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
EP0725653B2 (en) 1993-10-05 2008-04-02 UCB Pharma Limited Vaccine compositions
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US20040214157A1 (en) 1994-06-29 2004-10-28 Simon C. Burton Chromatographic resins and methods for using same
US5652348A (en) 1994-09-23 1997-07-29 Massey University Chromatographic resins and methods for using same
WO1996010089A1 (fr) 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification d'un peptide et d'une proteine
US5932714A (en) 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
EP1151098A1 (en) 1999-02-18 2001-11-07 Rmf Dictagene S.A. Malaria vaccine
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7781186B2 (en) 2000-09-25 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Screening methods using normal human liver cell line
WO2002026942A2 (en) 2000-09-25 2002-04-04 Walter Reed Army Institute Of Research Human liver cell line
US7363166B2 (en) * 2001-03-30 2008-04-22 Council Of Scientific & Industrial Research Computational method for the identification of candidate proteins useful as anti-infectives
SE0104353D0 (sv) 2001-12-19 2001-12-19 Amersham Biosciences Ab Separation method
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040067880A1 (en) 2002-10-04 2004-04-08 Kuo Macus Tien Prodrug therapy of liver diseases using receptor-mediated delivery of malarial circumsporozoite protein as a carrier
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
AU2004293810B2 (en) 2003-11-19 2010-07-01 Pelican Technology Holdings, Inc. Improved protein expression systems
WO2005089093A2 (en) 2003-11-21 2005-09-29 Dow Global Technologies Inc. Improved expression systems with sec-system secretion
WO2005063805A1 (en) 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
BRPI0506917A (pt) 2004-01-16 2007-06-05 Dow Global Technologies Inc expressão de proteìnas de mamìferos em pseudomonas fluorescens
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
WO2006023593A2 (en) 2004-08-20 2006-03-02 Kmt Hepatech, Inc. Malarial animal model having a chimeric human liver
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP1846023B1 (en) 2005-01-18 2013-09-25 Walter Reed Army Institute of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
EP1754717A1 (en) 2005-08-19 2007-02-21 Université de Lausanne Antigenic peptides and their use
DE602006015985D1 (de) 2005-09-30 2010-09-16 Philadelphia Health & Educatio Antigene gegen das leberstadium von plasmodium
US7749519B2 (en) 2005-12-09 2010-07-06 Kim Lee Sim Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
WO2007142954A2 (en) 2006-05-30 2007-12-13 Dow Global Technologies Inc. Codon optimization method
BRPI0807834A2 (pt) 2007-01-31 2014-07-22 Dow Global Technologies Inc " sequências-líder bacterianas para expressão aumentada ".
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9066899B2 (en) 2007-08-13 2015-06-30 Glaxosmithkline Biologicals Sa Vaccines
WO2009114202A2 (en) 2008-03-14 2009-09-17 The United States Of America As Represented By The Secretary Of The Navy Vaccine and immunization method using plasmodium antigen 2
WO2010008764A1 (en) 2008-06-23 2010-01-21 Dow Global Technologies Inc. Pseudomonas fluorescens strains for production of extracellular recombinant protein
CA2739568C (en) 2008-10-31 2015-12-01 Shujun Sun Purification of acidic proteins using ceramic hydroxyapatite chromatography
US8063193B2 (en) 2009-03-27 2011-11-22 Abbott Laboratories Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
MX2012010148A (es) 2010-03-04 2013-01-22 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
AU2011238711B2 (en) 2010-03-30 2015-06-18 Pelican Technology Holdings, Inc. High level expression of recombinant toxin proteins
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2385107B1 (en) 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Also Published As

Publication number Publication date
KR102087461B1 (ko) 2020-03-10
BR112014027019B1 (pt) 2022-09-06
TW201348250A (zh) 2013-12-01
US9849177B2 (en) 2017-12-26
US9169304B2 (en) 2015-10-27
EP2844666A4 (en) 2015-11-04
US20160051677A1 (en) 2016-02-25
EP2844666A1 (en) 2015-03-11
NZ630121A (en) 2016-06-24
TWI630213B (zh) 2018-07-21
JP6238967B2 (ja) 2017-11-29
CN104379596A (zh) 2015-02-25
KR20150027743A (ko) 2015-03-12
AU2013256757B2 (en) 2017-02-16
ZA201407420B (en) 2016-10-26
AR090900A1 (es) 2014-12-17
CA2870198A1 (en) 2013-11-07
CN104379596B (zh) 2018-05-29
WO2013165732A1 (en) 2013-11-07
AU2013256757A1 (en) 2014-10-30
SG11201407108TA (en) 2014-11-27
EP2844666B1 (en) 2019-07-17
MY166380A (en) 2018-06-25
MX352093B (es) 2017-11-08
MX2014013124A (es) 2015-02-05
US20140051841A1 (en) 2014-02-20
JP2015517464A (ja) 2015-06-22
CA2870198C (en) 2019-12-03

Similar Documents

Publication Publication Date Title
BR112014027019A2 (pt) processo para purificar proteína circunsporozoíta p. falciparum recombinante; formulação líquida estável de proteína circunsporozoíta p. falciparum recombinante; e processo para manter de forma estável rcsp em uma formulação líquida estável
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
BR112015021560A2 (pt) blenda de tensoativos para limpeza de membranas de filtração
IN2015KN00262A (pt)
BR112015022978A2 (pt) agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral
EA201790916A1 (ru) Новые лиганды rig-i и способы их получения
WO2013116501A3 (en) Sequences of 55 newly found proteins and their applications
GB2537077A (en) Methods for sequencing nucleic acids
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
SG194460A1 (en) Wash solution and method for affinity chromatography
WO2013030620A3 (de) Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem, protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz
WO2014178078A3 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
WO2012108726A3 (ko) 신규한 그래핀옥사이드 환원제 및 이에 의한 환원그래핀옥사이드의 제조방법
BR112016011224A2 (pt) Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc
BR112013010522A2 (pt) método para purificação de fator estimulador de colônias de granulócitos humano a partir recombinantes de e. coli
WO2010151632A8 (en) Protein purification by caprylic acid (octanoic acid ) precipitation
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
WO2014115037A3 (en) Beta-cryptoxanthin from plant source and a process for its preparation
IN2014DN08783A (pt)
MX2016002870A (es) Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
MX2016006558A (es) Sistesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexi l]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo.
WO2012158861A3 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
IN2014KN02722A (pt)
MY171770A (en) An apparatus for continuous separation of valine and a method for continuous separation of valine using the same

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2013, OBSERVADAS AS CONDICOES LEGAIS